F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 50 条
  • [11] F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia
    Depoortere, R.
    Bardin, L.
    Auclair, A. L.
    Slot, L. Bruins
    Kleven, M. S.
    Newman-Tancredi, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S434 - S434
  • [12] Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties
    Bardin, Laurent
    Kleven, Mark S.
    Barret-Grevoz, Catherine
    Depoortere, Ronan
    Newman-Tancredi, Adrian
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (09) : 1869 - 1879
  • [13] Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties
    Laurent Bardin
    Mark S Kleven
    Catherine Barret-Grévoz
    Ronan Depoortère
    Adrian Newman-Tancredi
    Neuropsychopharmacology, 2006, 31 : 1869 - 1879
  • [14] Antipsychotic-like effect and cataleptogenic potential of the dopamine D2 receptor partial agonist 2-bromoterguride
    Brosda, J.
    Franke, R.
    Jantschak, F.
    Pertz, H. H.
    Fink, H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S13 - S13
  • [15] L-stepholidine:: A D1 agonist D2 antagonist with an antipsychotic-like profile
    Mamo, DC
    Natesan, S
    VanderSpek, S
    Kapur, S
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 305 - 305
  • [16] Dopamine 1321133 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers
    Laszovszky, I.
    Nemeth, G.
    Meszaros, G. Pasztor
    Kapas, M.
    Brooks, D. J.
    Pavese, N.
    Szombathelyi, Z.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S455 - S455
  • [17] RGH-188, a d3/d2 dopamine receptor antagonist/partial agonist atypical antipsychotic candidate
    Laszlovszky, I.
    Kiss, B.
    Gyertyan, I.
    Meszaros, G. Pasztor
    Seneca, N.
    Schmidt, E.
    Nemethy, Z. S.
    Bugovics, G. Y.
    Saghy, K.
    Laszy, J.
    Kapas, M.
    Nemeth, G. Y.
    Szombathelyi, Z. S.
    EUROPEAN PSYCHIATRY, 2008, 23 : S163 - S163
  • [18] Neurochemical and behavioural actions of a novel dopamine D3/D2 receptor antagonist/partial agonist putative antipsychotic
    Kiss, B.
    Gyertyan, I.
    Saghy, K.
    Laszlovszky, I
    Horvath, A.
    Laszy, J.
    Schmidt, E.
    Szabo, Gy
    Againe, Csongor E.
    Adham, N.
    Tihanyi, K.
    Szombathelyi, Zs
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (09) : 1274 - 1275
  • [19] F17464, a Selective Dopamine D3 Antagonist/Serotonin 5-HT1A Partial Agonist, as a Clinical Candidate with Wide Ranging Antipsychotic-like Activity in Models of Dopamine and Glutamate Dysfunctions
    Sokoloff, Pierre
    Brunner, Valerie
    Tonner, Franc Oise
    Gaudoux, Florence
    Girgis, Ragy
    Slifstein, Mark
    Abi-Dargham, Anissa
    Leriche, Ludovic
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S571 - S571
  • [20] Cariprazine, a D3/D2 Dopamine Receptor Partial Agonist Antipsychotic, Displays Greater D3 Receptor Occupancy In Vivo Compared with Other Antipsychotics
    Kiss, Bela
    Horti, Ferenc
    Bobok, Amrita
    Adham, Nika
    BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 40S - 40S